AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Zai Lab Announces Upcoming Presentations at November Conferences

October 30, 2019 GMT

SHANGHAI, China and SAN FRANCISCO, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that members of the senior management team will be presenting at the following upcoming conferences this November. Details of the conferences are as follows:

Goldman Sachs China Conference 2019Presentation: Tuesday, November 5, 2019 at 3:15 p.m. CSTPresenter: Billy Cho, Chief Financial OfficerLocation: Ritz Carlton, Shenzhen, China

Jefferies China Summit 2019Presentation: Friday, November 15, 2019 at 8:30 a.m. CST Presenter: Billy Cho, Chief Financial OfficerLocation: JW Marriott, Hong Kong, China

BioCentury China Healthcare Summit 2019Presentation: Tuesday, November 19, 2019 at 9:00 a.m. CSTPresenter: Tao Fu, President & Chief Operating OfficerLocation: Jing An Shangri-La, Shanghai, China

Jefferies 2019 London Healthcare ConferencePresentation: Wednesday, November 20, 2019 at 1:20 p.m. GMTPresenter: Billy Cho, Chief Financial OfficerLocation: The Waldorf Hilton, London, UK

Goldman Sachs Asia Pacific Healthcare Forum 2019 Presentation: Monday, November 25, 2019 at 9:00 a.m. CSTPresenter: Samantha Du, Founder & Chief Executive OfficerLocation: Conrad, Hong Kong, China

A live webcast of the Jefferies 2019 London Healthcare Conference presentation will be available under “Events & Presentations” in the “Investor Relations” section of Zai Lab’s website. An archived replay will be available for 90 days following the event.

About Zai LabZai Lab (NASDAQ: ZLAB) is a China and U.S.-based innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Zai Lab’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China’s pharmaceutical market and addressing unmet medical needs. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners’ and its own products in order to impact human health worldwide.

For more information, please contact:

ZAI LAB CONTACTS:

Zai Lab Billy Cho, CFO +86 137 6151 2501 billy.cho@zailaboratory.com

Media: Ryo Imai / Robert Flamm, Ph.D. Burns McClellan, on behalf of Zai Lab 212-213-0006 ext. 315 / 364rimai@burnsmc.com / rflamm@burnsmc.com

Investors: Pete Rahmer Endurance Advisors, on behalf of Zai Lab 415-515-9763 prahmer@enduranceadvisors.com

Zai Lab Limited